MGMT and cancer: This interaction has been substantiated by clinical observations in patients with metastatic colorectal cancer, where a higher objective response rate to these alkylating agents has been correlated with the epigenetic silencing of the MGMT gene, an alteration that diminishes the DNA repair capacity of cancer cells, thereby enhancing the cytotoxic efficacy of the treatment (23, 24).